Why the study?
Does K-877 (Pemafibrate) attenuate postprandial hypertriglyceridemia more effectively than fenofibrate in mice?
Does K-877 (Pemafibrate) attenuate postprandial hypertriglyceridemia more effectively than fenofibrate in mice?
In a mouse model, the novel SPPARMα K-877 (pemafibrate) was more effective than fenofibrate at attenuating postprandial hypertriglyceridemia.
Should not change practice for PHTG; leaves open whether pemafibrate superiority over fenofibrate translates to humans.
K-877 may attenuate PHTG by suppressing the postprandial increase of chylomicrons and the accumulation of chylomicron remnants more effectively than fenofibrate.
No takes yet. Share an insight, caveat, or question.
Sairyo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: